{"id":"0d72f116-5e60-426c-80a6-afb2cf156c84","companyId":"8b13207b-ea44-42e3-8878-ec5f057b628b","modelName":"Oura Ring 4","slug":"oura-ring-4","description":"Oura (Oura Health, founded 2013 in Oulu, Finland) makes the Oura Ring, a biometric-primary titanium smart ring with sleep and readiness AI, recorded in the new biometric form factor, with the Oura Ring 4 from late 2024 introducing its Smart Sensing platform that expanded signal pathways from eight to eighteen on roughly an eight-day battery. It pairs heart-rate and heart-rate-variability, blood-oxygen-trend, multi-point temperature, and accelerometer sensing with sleep staging and a Sleep Score, a Readiness Score, activity, stress, cycle tracking with Natural Cycles integration, a VO2 Max estimate, and an AI Oura Advisor across more than 50 metrics, sold by purchase plus a required membership of $5.99 a month. On FDA status, the Oura Ring 4 itself has no clearance and is marketed as a general-wellness product, with its only cleared-feature route via partner integrations such as the FDA-cleared Natural Cycles birth-control app consuming Oura temperature data, where the clearance belongs to the partner. Oura is the disciplined counter-case to Whoop in the verified-versus-claimed framework: it launched a Blood Pressure Profile Study in December 2025 to pursue a hypertension feature, but that feature is investigational and not cleared, so Oura is running the clearance path before marketing blood pressure, in contrast to Whoop's market-first posture that drew an FDA warning letter. A valuation correction is worth recording: Oura is valued at $11 billion after a roughly $900 million Series E in October 2025 led by Fidelity with revenue reportedly above $1 billion in 2025, not the stale roughly $5 billion figure. Its clinical-validation posture is the strongest and growing in the cohort specifically on sleep, with a 2025 Brigham and Women's Hospital study finding it the most accurate consumer sleep tracker for four-stage classification against polysomnography, while its posture is validated wellness rather than a cleared medical device except via partners, and its blood-pressure feature and the accuracy of its Readiness and VO2 Max metrics are investigational or not clearance-validated.","formFactor":"biometric","maturityStage":"commercial","lifecycleState":"active","supersededByModelId":null,"specs":{"notes":[{"label":"FDA clearances (minimal - the disciplined posture)","value":"The Oura Ring 4 itself has NO FDA clearance; it is marketed as a GENERAL-WELLNESS product under FDA's general-wellness policy. Cleared-feature route is via PARTNER integrations (e.g. Natural Cycles, an FDA-cleared birth-control app, consuming Oura temperature data - the clearance belongs to Natural Cycles, not Oura)."},{"label":"Disciplined counter-case to Whoop (verified-vs-claimed)","value":"Oura launched a Blood Pressure Profile Study (Dec 2025) pursuing a hypertension feature, but it is INVESTIGATIONAL and NOT cleared - Oura is running the study/clearance path BEFORE marketing BP. This is the disciplined counter-case to Whoop's market-first posture (which drew an FDA warning letter for marketing uncleared BP)."},{"label":"CORRECTION (valuation)","value":"Valuation is $11B (Series E ~$900M, Oct 2025, Fidelity-led; revenue reportedly >$1B in 2025) - NOT the stale ~$5B+."},{"label":"Verification posture","value":"Boundary: biometric-primary + AI-augmented. Clinical posture: STRONGEST/growing on SLEEP (2025 Brigham & Women's study found Oura the most accurate consumer sleep tracker for 4-stage classification vs PSG; ~94% sleep/wake sensitivity vs PSG; 2026 meta-analysis corroborated). Posture is 'validated wellness', not 'cleared medical device' (except via partners). NOT verified: BP/hypertension feature (investigational); Readiness/VO2 Max accuracy (not clearance-validated)."}],"specs":"Oura Ring 4 (Gen 4, late 2024). Titanium smart ring; 'Smart Sensing' (recessed sensors, signal pathways 8->18); ~8-day battery. Sensors: PPG HR + HRV, red/IR blood-oxygen (SpO2 trends), multi-point skin temperature, accelerometer. Outputs: Sleep staging + Sleep Score, Readiness Score, Activity, stress, Cycle tracking + Natural Cycles integration, VO2 Max estimate, AI 'Oura Advisor' (LLM). 50+ metrics. Founded 2013, Oulu Finland. Purchase (~$349+) + REQUIRED Oura Membership ($5.99/mo).","formFactor":"biometric (biometric-primary smart ring + AI augmentation; sleep/readiness; general-wellness)"},"manufacturerSerial":null,"reviewStatus":"reviewed","sources":[{"url":"https://www.cnbc.com/2025/10/14/oura-smart-ring-11-billion-valuation.html","title":"Oura raises ~$900M Series E at $11B valuation (Oct 2025; Fidelity-led)","sourceName":"CNBC"},{"url":"https://ouraring.com/blog/oura-ring-4/","title":"Oura Ring 4 (Gen 4, late 2024): Smart Sensing, signal pathways 8->18; sleep/readiness/temp; AI Advisor","sourceName":"Oura (official)"},{"url":"https://www.medtechdive.com/news/oura-blood-pressure-fda-study/","title":"Oura pursuing a hypertension feature via a Blood Pressure Profile Study (Dec 2025; investigational)","sourceName":"MedTech Dive"},{"url":"https://sleepreviewmag.com/sleep-diagnostics/consumer-sleep-tracking/oura-ring-4-sleep-accuracy/","title":"Oura Ring sleep-staging validated PSG-comparable (Brigham & Women's study)","sourceName":"Sleep Review"}],"aliases":["Oura Ring","Oura Ring 4","Oura Ring Gen 4"],"collisionRisk":"low","reviewNote":null,"manufacturerTermForTeleop":null,"createdAt":"2026-06-03T22:32:18.390Z","updatedAt":"2026-06-03T22:32:18.390Z","jsonLd":{"@context":"https://schema.org","@type":"Product","@id":"https://registry.deploy.report/models/oura-ring-4","url":"https://registry.deploy.report/models/oura-ring-4","name":"Oura Ring 4","alternateName":["Oura Ring","Oura Ring 4","Oura Ring Gen 4"],"description":"Oura (Oura Health, founded 2013 in Oulu, Finland) makes the Oura Ring, a biometric-primary titanium smart ring with sleep and readiness AI, recorded in the new biometric form factor, with the Oura Ring 4 from late 2024 introducing its Smart Sensing platform that expanded signal pathways from eight to eighteen on roughly an eight-day battery. It pairs heart-rate and heart-rate-variability, blood-oxygen-trend, multi-point temperature, and accelerometer sensing with sleep staging and a Sleep Score, a Readiness Score, activity, stress, cycle tracking with Natural Cycles integration, a VO2 Max estimate, and an AI Oura Advisor across more than 50 metrics, sold by purchase plus a required membership of $5.99 a month. On FDA status, the Oura Ring 4 itself has no clearance and is marketed as a general-wellness product, with its only cleared-feature route via partner integrations such as the FDA-cleared Natural Cycles birth-control app consuming Oura temperature data, where the clearance belongs to the partner. Oura is the disciplined counter-case to Whoop in the verified-versus-claimed framework: it launched a Blood Pressure Profile Study in December 2025 to pursue a hypertension feature, but that feature is investigational and not cleared, so Oura is running the clearance path before marketing blood pressure, in contrast to Whoop's market-first posture that drew an FDA warning letter. A valuation correction is worth recording: Oura is valued at $11 billion after a roughly $900 million Series E in October 2025 led by Fidelity with revenue reportedly above $1 billion in 2025, not the stale roughly $5 billion figure. Its clinical-validation posture is the strongest and growing in the cohort specifically on sleep, with a 2025 Brigham and Women's Hospital study finding it the most accurate consumer sleep tracker for four-stage classification against polysomnography, while its posture is validated wellness rather than a cleared medical device except via partners, and its blood-pressure feature and the accuracy of its Readiness and VO2 Max metrics are investigational or not clearance-validated.","identifier":"0d72f116-5e60-426c-80a6-afb2cf156c84","category":"biometric","publisher":{"@id":"https://deploy.report/#organization"}}}